Compare Standard Lithium Ltd (SLI) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Standard Lithium Ltd vs 10X Genomics Inc — how do they compare? Standard Lithium Ltd trades at $2.42 (market cap $604.50M), while 10X Genomics Inc trades at $57.7 (market cap $7.61B). The key difference: 10X Genomics Inc is far larger — about 12.6× Standard Lithium Ltd's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals.
| SLI | TXG | |
|---|---|---|
Market Cap | $604.50M | $7.61B |
Sector | Basic Materials | Health |
52-Week High | $5.65 | $58.57 |
52-Week Low | $1.93 | $11.34 |
Enterprise Value | $467.42M | $7.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLI trades at $2.41, down 4.74% today, with a bullish technical signal from moving averages and a neutral oscillator stance. The company reported a net loss of $48.40M in 2025, with negative ROE and ROA, but beat EPS estimates in two recent quarters. Positive news includes a $225M DOE grant and progress on its South West Arkansas lithium project, with institutional buying from Amundi (64.9% stake increase in Q1 2026 per SEC filing).
The outlook hinges on project execution, as SLI transitions to production with strong analyst support (100% buy ratings). Key risks include cash burn from negative operating cash flow and reliance on financing, but de-risking milestones and government backing offer upside if timelines are met.
TXG trades at $57.77, down 1.37% today, with a bullish technical outlook supported by moving averages and strong support at $55. The company shows improving fundamentals with Q2 2026 earnings beating estimates and positive cash flow trends, though it remains unprofitable with negative margins. Recent news highlights collaborations with major medical institutions and strategic acquisitions expanding multiomics capabilities.
Investment outlook is mixed: technical strength and analyst upgrades suggest near-term upside potential, but high valuation multiples and persistent losses pose significant risks. The stock faces pressure from competitive threats and execution challenges in achieving profitability, requiring careful monitoring of upcoming Q3 earnings and revenue growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
